Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of HTL0022562 in Healthy Adults
NCT04941989Phase 1Terminated
- Sponsor
- Nxera Pharma
- Start
- May 2021
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HTL-0022562 in migraine (2 arms), sponsored by Nxera Pharma. Primary endpoint: Number of Treatment Emergent Adverse Events at Day 15. Started May 2021; status: terminated.
02
Drugs
HTL-0022562
03
Conditions
migraine
Beyond the preview
Go deeper on NCT04941989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04941989.